GLP-1 and gip receptor agonists

Intervention1 paper1 finding

Associations

1

Type 2 diabetes

downin humans1High certainty

1 study

GLP-1 and gip receptor agonists lower the risk of type 2 diabetes in humans (RR = .1, CI [.05; .21]).
Human trialprediabetes
Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials · Clinical and translational medicine · 1 Sep 2026

Type 2 diabetes →

Funding

National Institute of Diabetes and Digestive and Kidney DiseasesUS$288.2k1 grant since 2026

Production in maize of low-cost heat stable forms of GLP-1 and GIP receptor agonists for treatment of diabetes and obesity
National Institute of Diabetes and Digestive and Kidney DiseasesApplied Biotechnology InstituteUS$288.2k2026–2028

Latest

1

Clinical and Translational MedicineReview9 Sep

Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials